XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 5,056 $ 5,530
Short-term investments 14,081 5,708
Prepaid expenses and other current assets 1,305 367
Total current assets 20,442 11,605
Property and equipment, net 138 167
Other assets 472 413
Total assets 21,052 12,185
Current liabilities:    
Accounts payable 2,144 1,419
Accrued clinical trial costs 829 1,141
Accrued expenses 941 1,468
Total current liabilities 3,914 4,028
Warrant liability 3,300 0
Total liabilities 7,214 4,028
Commitments and contingencies (Note 9)
Stockholders' equity    
Preferred stock, $0.0001 par value; 10,000,000 shares and no shares authorized at June 30, 2024 and December 31, 2023, respectively; no shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023; 10,750,156 and 5,754,505 issued and outstanding at June 30, 2024 and December 31, 2023, respectively 3 1
Additional paid-in capital 163,732 154,218
Accumulated deficit (149,888) (146,064)
Accumulated other comprehensive income (loss) (9) 2
Total stockholders' equity 13,838 8,157
Total liabilities and stockholders' equity $ 21,052 $ 12,185